About 7% of Americans have asthma, and population prevalence estimates are as high as 18% in some countries. [1] Given its burden to global health, significant resources have been devoted to studying ...

Exploration of key clinical trial data and real-world evidence on dupilumab in asthma and COPD presented at the ERS and CHEST ...

Credit: Getty Images The GINA 2024 asthma update includes new guidance on medications, monitoring, treatment goals, remission, cough variant asthma, children, and more. The Global Initiative for ...

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease ...

Please provide your email address to receive an email when new articles are posted on . Fewer patients achieved remission with mepolizumab when more stringent definitions including lung function were ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

This year’s top asthma and respiratory disorder story focused on the pushback from multiple advocacy groups following ...

New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthma Lunsekimig now targeting chronic rhinosinusitis and COPD in addition to asthma Itepekimab expanding into chronic ...

Recent guidelines have renewed the focus on treating severe asthma. During 2 panels at CHEST 2020, experts discussed key updates, limitations of the guidelines, and more. Recent updates to the Global ...

All that wheezes is not pediatric asthma Many upper- and lower-airway problems can cause wheeze and cough, and some conditions coexist with asthma. Here's how to pin down a diagnosis. Asthma causes ...

WALTHAM, Mass.--(BUSINESS WIRE)--Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, today announced the dosing of the first patients in its Phase 2 VALIANT ...